The Neurology Pipeline: A Strategic Review

Published by	Decision Resources, Inc.
Published	August, 2009	Product code	97066
Content info	39 Pages
Price	US $ 3450 PDF by E-mail (Global License)

Introduction
Related Reports

The Neurology Pipeline: A Strategic Review published by Decision Resources, Inc. in August, 2009. This report consists of 39 Pages and the price starts from US $ 3450.

Introduction

Abstract

Introduction

Mega-blockbuster status would be quick and sure for any safe, effective agent that prevents the death and damage of neurons associated with neurodegenerative diseases. The potential of such a neuroprotectant is one of the motivations for the 188 companies currently involved in the development of 263 neurological pipeline agents, despite the plethora of marketed agents for these diseases and disorders. Meanwhile, less-debilitating neurological disorders that nonetheless affect patients' quality of life (e.g., migraine, insomnia) also face significant unmet needs. Today' s pipeline of new molecular entities (NMEs) and reformulations holds a range of agents with potential to improve treatment and infl uence market dynamics, as well as drive market growth through 2015.

Questions Answered in This Report

The neurology market experienced steady growth from 2004 through 2008. Which drug classes contributed most to this increase in sales? Which drug classes are projected to contribute to an increase or decrease in future sales?
Clinical trial design and end points are a significant constraint on drug development and market growth in the neurology indication. Which neurology indications are particularly affected by these constraints? What specific effects do these constraints have on the market?
The development of a safe, efficacious neuroprotectant is the elusive “holy grail” in the neurology market. Why is the development of a neuroprotectant so tantalizing to the neurology field? What barriers have prevented the development and launch of a successful neuroprotectant? Which companies have latestage neuroprotectants in the pipeline?
The neurology market is significant in terms of sales and is projected to continue growing in the near future. Which companies are the current market leaders, and which companies are projected to be the market leaders in 2015? Which companies are attempting to enter, grow, or protect their position in this market? Which indications will drive the majority of the growth?

Scope

The neurology pipeline: Number of agents in development; disease focus; NMEs versus reformulations; formulations by disease; drug targets; phase analysis; development by company type; number of agents by phase; number of agents by disease; profiles of GlaxoSmithKline, Roche, and Eli Lilly.
Historical and projected neurology sales: 2004-2015 sales; leading drug classes; current and projected market-leading companies; key patent expiries impacting neurology sales; R&D spend of market-leading companies.
Market opportunities/drivers: Room for an effective neuroprotectant; new formulations/delivery systems; an aging population.
Market constraints: Clinical trial end points; time to treatment versus disease progression; generics.

Companies Mentioned in This Report

Abbott Laboratories
Aguettant
Alliance Pharma
Almirall
Amgen
Aspreva
Astellas Pharma
AstraZeneca
Banyu Seiyaku
Baxter International
Bayer Schering
Biofutura
Biogen Idec
Boehringer Ingelheim
Bracco
Bristol-Myers Squibb
Britannia Pharmaceuticals
Cambridge Labs
Cephalon
Chiesi
Chugai Seiyaku
Daiichi Sankyo
Dainippon Sumitomo
Dava Pharmaceuticals
Desma
DuPont Pharma
Eisai
Eli Lilly
Endo Pharmaceuticals
Esteve
Forest Laboratories
Genentech
GlaxoSmithKline
Grupo Ferrer
Grupo Grunenthal
Impax Laboratories
Janssen
Johnson & Johnson
King Pharmaceuticals
Kyowa Hakko Kirin
Lundbeck
Meda
Menarini
Merck & Co.
Merck Serono
Merz
Mitsubishi Tanabe Pharma
Novartis
Onko
Organon
Orion
Orphan Europe
Ortho-McNeil Neurologics
Par Pharma
Pfizer
Prometheus Laboratories
Roche
Sanofi-Aventis
Schwartz Pharma
Sepracor
Shire Pharmaceuticals
Solvay
Takeda
Teofarma
Teva
UCB
Valeant Pharma
Vernalis
Wyeth

Major Neurological Diseases Mentioned in This Report

Alzheimer' s disease (AD)
Amyotrophic lateral sclerosis (ALS)
Epilepsy
Huntington' s disease (HD)
Insomnia
Migraine
Multiple sclerosis (MS)
Parkinson' s disease (PD)
Restless legs syndrome (RLS)
Stroke

Executive Summary
- Strategic Considerations
- Stakeholder Implications
Introduction
The Neurological Disease Pipeline
- Agents
- Companies
  - GlaxoSmithKline
  - Roche
  - Eli Lilly
Opportunities in the Neurology Pipeline
- Great Potential for an Effective Neuroprotectant
- More-Convenient/Safer Formulations of Neurology Drugs
Market Statistics and Market Outlook
- Market Statistics
- Market Drivers and Constraints